News for hackers. Stuff that matters.
Re:Coronavirus human challenge study gets green light in UK by graeme on Wednesday February 17, 2021 @04:35PM (#26172104)
Every vaccine we have developed in the past had reduced transmission. No exceptions. It is scientific blindness to abandon all of our priors and say “who knows if it reduces transmission?”
Re:Coronavirus human challenge study gets green light in UK by oldgradstudent on Wednesday February 17, 2021 @04:49PM (#26172271)
There are exceptions.

The Tetanus vaccine targets the toxin, not the pathogen.

Some research may indicate that the current a-cellular whooping cough vaccine prevents symptoms, but not transmission. The older vaccine prevented transmission, but had too many side effects.

The oral polio vaccine may actually result in outbreaks of the vaccine strain.

http://www.emro.who.int/syr/syria-news/polio-outbreak-succes...

Claims about prevention of transmission needs to be demonstrated in a trial, not simply asserted.

Re:Coronavirus human challenge study gets green light in UK by maxerickson on Wednesday February 17, 2021 @05:12PM (#26172511)
So would you expect a vaccine that is targeted at a viral protein to target something other than the viral protein?
Re:Coronavirus human challenge study gets green light in UK by oldgradstudent on Wednesday February 17, 2021 @05:25PM (#26172639)
I have no idea. But I see no reason to a-priori assume perfect targeting without a trial.

Supposedly, the Pandemrix fiasco happened because the antibodies generated by the vaccine cross reacted with some human proteins.

The lengthy drug approval regimen exists not because of some power drunk bureaucrats. It exists because of a long history of dangerous and ineffective drugs that looked really great in theory.

Re:Coronavirus human challenge study gets green light in UK by graeme on Wednesday February 17, 2021 @05:52PM (#26172917)
The antibodies in pandremix would have had the same effect had those who were vaccinated been infected by the flu instead, except the narcolepsy would have been worse.
Re:Coronavirus human challenge study gets green light in UK by oldgradstudent on Wednesday February 17, 2021 @06:12PM (#26173129)
Or another, safer, vaccine could have been used instead.
Re:Coronavirus human challenge study gets green light in UK by maxerickson on Wednesday February 17, 2021 @06:32PM (#26173328)
I was more ragging on the tetanus paragraph.
Re:Coronavirus human challenge study gets green light in UK by graeme on Wednesday February 17, 2021 @05:36PM (#26172740)
Tetanus does not transmit person to person and so is a poor example. In particular since the coronavirus vaccines do target the pathogen.

Likewise, it is not surprising that injecting a live polio virus can cause an infection. That is a different claim than saying a vaccinated person will get infected and transmit later once immune. Further, the coronavirus vaccines do not use live viruses.

Whooping cough is the example people love to bring up. I’ll paste in full my prior comment on this. The worst case example reduces transmission at least 30%! And probably more: it was completely sterilizing in 30% but may well have reduced transmissibility in other groups. And that’s the very worst case vaccine.

———————-

I looked into this, and it does seem the vaccine reduces transmission. It just doesn’t stop it entirely. The paper below is Wikipedia’s source. Upon a close read, in the daycare there were three groups of vaccinated children: * Those positive for antibodies but pcr negative —> had been exposed, cleared virus without infection * those pcr positive but asymptomatic * those pcr positive and symptomatic About 30% were in the seropositive group which didn’t have pcr positivity. So it seems like transmission was reduced at least 30%. It’s also possible the other two groups would have had lower transmission rates than if they had had no vaccine. If you have a more precise source I’d be interested to see it, but if this is the worst case it’s pretty good! > We used PCR, EIA, and culture to confirm B. pertussis infection in two highly vaccinated groups of children in two day-care centers. Three (10%) of 30 2- to 3-year-old children were seropositive for recent infection; one had nasopharyngeal colonization and a clinical illness that met the modified WHO case definition. In the day-care center for the 5- to 6- year-old group, 9 (55%) of 16 children were IgM positive, 4 (25%) of whom had nasopharyngeal colonization. Of these four children, three had nonspecific cough, and only one met the modified WHO definition for pertussis. None of the children in our study, including those who met the WHO definition, had been examined by a physician before our investigation. >Children who were seropositive and re- mained both asymptomatic and PCR negative probably had sufficient immunity from vaccines or natural boosters to protect them against persistent colonization and clinical disease. Their seropositivity could not be due to vaccine because the children were tested more than a year after having been vaccinated.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2627963/pdf/109...

https://news.ycombinator.com/item?id=25903787

Re:Coronavirus human challenge study gets green light in UK by oldgradstudent on Wednesday February 17, 2021 @06:07PM (#26173091)
I am not sure how do you draw these conclusions from the study.

There's no comparison between transmission by vaccinated and non-vaccinated children, so there's no possible way of concluding that vaccination reduced transmission relative to non-vaccination.

Re:Coronavirus human challenge study gets green light in UK by graeme on Wednesday February 17, 2021 @06:17PM (#26173175)
Among the vaccinated students 30% showed antibodies but were pcr negative. Hence they had fought off an infection but had no trace of replication.

You would not expect to see seropositive but pcr negative students if unvaccinated.

Re:Coronavirus human challenge study gets green light in UK by runako on Wednesday February 17, 2021 @04:40PM (#26172152)
I'm not suggesting we abandon priors, but Covid does have some novel facts:

- apparently high asymptomatic rate

- somewhat unpredictable who will get severe case

- random neurological symptoms in a respiratory virus

And most/all of the vaccines we are using will be the first approved for human use on their respective platforms. It's worth looking at.

Also, for a pathogen that is so highly transmissible, it's worth understanding what we mean by "reduced transmission". Is it 10% less? 90%? Surely this would be important to know before following a strategy of vaccinating the young and healthy first. (Especially given the difficulty of doing so in a population that is least likely to suffer serious harm from the pathogen.)

Re:Coronavirus human challenge study gets green light in UK by graeme on Wednesday February 17, 2021 @05:51PM (#26172903)
The point is we could have vaccinated the young and healthy summer 2020, had we had challenge trials proving efficacy in that group. How could that not have helped?

We vaccinated no one in that period as it is.

Re:Coronavirus human challenge study gets green light in UK by runako on Wednesday February 17, 2021 @06:39PM (#26173414)
Even a challenge trial would need to be run properly and include enough people to generate useful data. But let's play the opposite. Let's be unscientific and assume an untested vaccine on a novel platform would reduce transmission risk (Edit: if we assume this, why not just assume the candidate vaccine works and just skip the challenge trials too?). Further assume that recruiting enough volunteers for meaningful results would be easy in spring 2020, before the age cohort differences in severity were as established.

Given those assumptions, there still needs to be a smaller safety trial before a large challenge trial. BioNTech started those in April, that ended in May. Deployment in the summer is already aggressive, assuming no challenge trials and we had just deployed vaccines shown to be safe in very small trials.

But suppose a challenge trial was run rapidly over the next three months (to determine which of the BioNTech candidates was best). Assume this all goes optimally. This plan still assumes the existence of scale manufacturing facilities that likely did not exist last summer. Let's wish that away too, so we have scaled manufacturing capacities to June 2021 levels by May 2020. While we have our magic wand out, let's wave away the fact that the vaccine initially took over 100 days to manufacture, so that in our world we can decide what to produce today and have it ready tomorrow instead of next quarter. So we've got positive challenge trial results in July 2020 with faster-than-2021 production capacity to go to scale.

Now, perception-wise, we are asking young healthy people to take a vaccine designed on a novel platform that was rushed through a novel ethics-skirting approval process, for a virus that likely won't seriously harm them if they get it. I'm not sure that would be as effective as people seem to think it is.

Re:Coronavirus human challenge study gets green light in UK by tinus_hn on Wednesday February 17, 2021 @05:53PM (#26172932)
We didn’t even bother manufacturing vaccines. Even though they were paid in advance.
Re:Coronavirus human challenge study gets green light in UK by graeme on Wednesday February 17, 2021 @06:18PM (#26173180)
Because there was no one approved to give them to. Companies could have gone some out if govts had ordered delivery earlier for the age groups in question.

It would have sped up subsequent production too.

Re:Coronavirus human challenge study gets green light in UK by tinus_hn on Wednesday February 17, 2021 @07:33PM (#26173874)
The orders were placed and guaranteed over half a year ago. Don’t make up excuses.